Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

StockNews.com lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday morning. Other analysts have also ...

Q4 2024 Earnings Call Transcript February 13, 2025 Bio-Rad Laboratories, Inc. beats earnings expectations. Reported EPS is $2 ...

Bio-Rad Laboratories' cost-cutting plans come as the company swung to a loss in the fourth quarter amid lower sales across its life-science segment. The company posted a net loss of $715.8 million, or ...

Bio-Rad has entered a binding offer to purchase all equity interests in French biotech Stilla Technologies. According to ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...